Literature DB >> 3300461

Immunology of human immunodeficiency virus infection and the acquired immunodeficiency syndrome. An update.

M Seligmann, A J Pinching, F S Rosen, J L Fahey, R M Khaitov, D Klatzmann, S Koenig, N Luo, J Ngu, G Riethmüller.   

Abstract

Recent advances in the understanding of the pathogenesis of infection with human immunodeficiency virus (HIV) stems from the demonstration that the membrane glycoprotein, CD4, is the cellular receptor for HIV. This glycoprotein is found mainly on the surface of a major subpopulation of T lymphocytes and also on macrophages, natural killer cells, some B lymphocytes, and neuronal cells. Cells infected with HIV may be destroyed or have their normal function impaired. Host immune responses to HIV are poor and are not sustained. Neutralizing antibody often is not produced, or HIV may escape from normal immunosuppressive mechanisms through the process of rapid antigenic variation. Factors and markers that may be important in the outcome or that may predict progression of HIV infection are genetic (Gc type), environmental (nutritional status or intercurrent sexually transmitted diseases sustained by the host), and immunologic (rate of decline in number and impairment of function of CD4 lymphocytes and of decline in antibody titers to HIV core protein, p24). A recombinant vaccine will probably be developed for testing in future clinical trials.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3300461     DOI: 10.7326/0003-4819-107-2-234

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  18 in total

1.  Spontaneous release of interferon as a predictor of clinical evolution in HIV-positive subjects.

Authors:  A Biglino; A Surbone; F Lipani; N Cappello; B Forno; A M Pollono; M Busso; A Pugliese
Journal:  Infection       Date:  1991 Jan-Feb       Impact factor: 3.553

Review 2.  Human immunodeficiency virus infection and the rheumatologist.

Authors:  I F Rowe; A C Keat
Journal:  Ann Rheum Dis       Date:  1989-02       Impact factor: 19.103

3.  Serum non-organ specific autoantibodies in human immunodeficiency virus 1 infection.

Authors:  F Cassani; L Baffoni; E Raise; L Selleri; M Monti; L Bonazzi; F M Gritti; F B Bianchi
Journal:  J Clin Pathol       Date:  1991-01       Impact factor: 3.411

4.  IgG subclass response to HIV in relation to antibody-dependent cellular cytotoxicity at different clinical stages.

Authors:  K Ljunggren; P A Broliden; L Morfeldt-Månson; M Jondal; B Wahren
Journal:  Clin Exp Immunol       Date:  1988-09       Impact factor: 4.330

Review 5.  Pediatric human immunodeficiency virus infection.

Authors:  J B Domachowske
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

6.  Quantitative western immunoblotting analysis in survey of human immunodeficiency virus-seropositive patients.

Authors:  D G Schiavini; J M Puel; S A Averous; J A Bazex
Journal:  J Clin Microbiol       Date:  1989-09       Impact factor: 5.948

7.  Prevalence of antibodies to human herpesviruses and hepatitis B virus in patients at different stages of human immunodeficiency virus (HIV) infection.

Authors:  R Enzensberger; W Braun; C July; E B Helm; H W Doerr
Journal:  Infection       Date:  1991 May-Jun       Impact factor: 3.553

8.  The defect seen in the phosphatidylinositol hydrolysis pathway in HIV-infected lymphocytes and lymphoblastoid cells is due to inhibition of the inositol 1,4,5-trisphosphate 1,3,4,5-tetrakisphosphate 5-phosphomonoesterase.

Authors:  K E Nye; G A Riley; A J Pinching
Journal:  Clin Exp Immunol       Date:  1992-07       Impact factor: 4.330

9.  Activation of human peripheral blood mononuclear cells by interleukin-2 and granulocyte-macrophage colony-stimulating factor to inhibit Cryptococcus neoformans.

Authors:  S M Levitz
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

10.  Preventing secondary infections among HIV-positive persons.

Authors:  G A Filice; C Pomeroy
Journal:  Public Health Rep       Date:  1991 Sep-Oct       Impact factor: 2.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.